Navigation Links
LDL particle measurement by NMR recognized by ADA, ACC
Date:3/28/2008

Raleigh, NC, March 28, 2008 - The American Diabetes Association (ADA) and the American College of Cardiology (ACC) issued a consensus statement today that states the measurement of LDL particle number by nuclear magnetic resonance (NMR) is one of the more accurate ways to evaluate cardiometabolic risk (CMR). The study, published in the April issue of Diabetes Care, reinforces that LDL cholesterol may not be the best way to quantify a patients risk for cardiovascular disease (CVD).

Cardiometabolic Risk (CMR) is associated with Type 2 Diabetes and CVD obesity, insulin resistance, hyperglycemia and hypertension are risk factors that often cluster together. ApoB and LDL particle concentration appear to be more closely associated with these markers of CMR than LDL cholesterol or non-HDL cholesterol. Subsequently, lipoprotein abnormalities are commonly found in patients with CMR. According to the consensus statement, ApoB and LDL particle number by NMR appear to be more discriminating measures of the adequacy of LDL lowering therapies than are traditional LDL and HDL cholesterol measures.

"Several studies have shown that LDL cholesterol (LDL-C) poorly characterizes lipid abnormalities in patients with cardiometabolic risk," says Robert S. Rosenson, MD, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research, University of Michigan School of Medicine and presenter at the consensus panel meeting. "Additionally, LDL-P concentrations, compared to LDL-C and non HDL-C, have been shown to be stronger predictors of cardiovascular risk."

The NMR LipoProfile test, developed by LipoScience, Inc., is the only test that quantifies LDL particle number (LDL-P) using Nuclear Magnetic Resonance. LDL particle information is used by clinicians to monitor the effect of lipid altering interventions, such as statins, in the management of a patients cardiovascular health by lowering LDL particle number (LDL-P).

Studies show that low concentrations of LDL particles are associated with fewer cardiovascular disease related events than equivalently low levels of LDL cholesterol; data most recently published from the Framingham Offspring study in December 2007.1

This consensus statement further demonstrates the critical role that the NMR LipoProfile test can play for the millions of people with diabetes or cardiovascular disease risk, says Rick Brajer, Chief Executive Officer and President, LipoScience, Inc. Measuring LDL particle number by NMR presents physicians and patients with the opportunity to better manage cardiometabolic risk.


'/>"/>

Contact: Maura Siefring
msiefring@dorland.com
267-765-3974
Dorland Global Public Relations
Source:Eurekalert

Related biology news :

1. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
2. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
3. New nanoparticle vaccine is more effective but less expensive
4. Nanoparticle exposures happen, says expert
5. Worldwide atmospheric measurements will determine the role of atmospheric fine particles
6. MIT: Remote-control nanoparticles deliver drugs directly into tumors
7. MIT sculpts 3-D particles with light
8. Technique controls nanoparticle size, makes large numbers
9. Tiny dust particles from Asian deserts common over western United States
10. Particle accelerator may reveal shape of alternate dimensions
11. Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology: